A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms MAESTRO
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 01 May 2020 Primary endpoint (Change in the mean daily Overactive Bladder-Symptom Composite Score) has not been met as per results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology